Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACT2 trial of accelerated adjuvant chemotherapy with capecitabine in early breast cancer
ISRCTN68068041Phase 3Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Dec 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cyclophosphamide, methotrexate, fluorouracil and capecitabine in breast cancer (4 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Disease-free survival. Started Dec 2005; status: completed.
02
Drugs
epirubicincyclophosphamidemethotrexatefluorouracilcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN68068041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68068041.